Le, X., Puri, S., Negrao, M. V., Nilsson, M. B., Robichaux, J., Boyle, T., . . . Heymach, J. V. (2018). Landscape of EGFR -dependent and -independent resistance mechanisms to osimertinib and continuation therapy post-progression in EGFR-mutant NSCLC. Clin Cancer Res.
Stile di citazione ChicagoLe, Xiuning, et al. "Landscape of EGFR -dependent and -independent Resistance Mechanisms to Osimertinib and Continuation Therapy Post-progression in EGFR-mutant NSCLC." Clin Cancer Res 2018.
Citazione MLALe, Xiuning, et al. "Landscape of EGFR -dependent and -independent Resistance Mechanisms to Osimertinib and Continuation Therapy Post-progression in EGFR-mutant NSCLC." Clin Cancer Res 2018.
Attenzione: Queste citazioni potrebbero non essere precise al 100%.